10 Dec 2024 • A real-world analysis of over 684,000 adults with type 2 diabetes found that both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of incident pneumonia and severe sepsis.

SGLT2i use was linked to a 25% lower risk of both conditions, while GLP-1 RA treatment showed an even greater reduction, with a 40% decreased risk compared to dipeptidyl peptidase-4 inhibitors (DPP-4i).

These findings highlight the potential additional benefits of these drugs beyond glucose control and cardiovascular protection, warranting further research to explore their broader clinical implications.

Source: BMJ | Read Full Story